CA2002247A1 - Inhibiteurs de la dopamine-.beta.-hydroxylase - Google Patents

Inhibiteurs de la dopamine-.beta.-hydroxylase

Info

Publication number
CA2002247A1
CA2002247A1 CA002002247A CA2002247A CA2002247A1 CA 2002247 A1 CA2002247 A1 CA 2002247A1 CA 002002247 A CA002002247 A CA 002002247A CA 2002247 A CA2002247 A CA 2002247A CA 2002247 A1 CA2002247 A1 CA 2002247A1
Authority
CA
Canada
Prior art keywords
compound
formula
4alkyl
compounds
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002002247A
Other languages
English (en)
Inventor
Lawrence I. Kruse
Stephen T. Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CA2002247A1 publication Critical patent/CA2002247A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002002247A 1988-12-01 1989-11-06 Inhibiteurs de la dopamine-.beta.-hydroxylase Abandoned CA2002247A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27862288A 1988-12-01 1988-12-01
US07/278,622 1988-12-01

Publications (1)

Publication Number Publication Date
CA2002247A1 true CA2002247A1 (fr) 1990-06-01

Family

ID=23065696

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002002247A Abandoned CA2002247A1 (fr) 1988-12-01 1989-11-06 Inhibiteurs de la dopamine-.beta.-hydroxylase

Country Status (6)

Country Link
EP (1) EP0371730A1 (fr)
JP (1) JPH02193978A (fr)
AU (1) AU4553889A (fr)
CA (1) CA2002247A1 (fr)
DK (1) DK593489A (fr)
PT (1) PT92473A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110007A1 (fr) * 2007-03-12 2008-09-18 The Royal Institution For The Advancement Of Learning/Mcgill University Oligomères ioniques de type imidazolium

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438150A (en) * 1994-04-26 1995-08-01 Syntex (U.S.A.) Inc. Process for making 1-benzocycloalkyl-1,3-dihydroimidazole-2-thione derivatives
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5414010A (en) * 1994-05-10 1995-05-09 Warner-Lambert Company Dimeric benzimidazoles as central nervous system agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT78388B (en) * 1983-04-12 1986-09-15 Smithkline Beckman Corp Dopamine-beta-hydroxylase inhibitors
IL82401A0 (en) * 1986-05-06 1987-11-30 Merrell Dow Pharma Dopamine beta hydroxy-lase inhibiting imidazole derivatives and pharmaceutical compositions containing them

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110007A1 (fr) * 2007-03-12 2008-09-18 The Royal Institution For The Advancement Of Learning/Mcgill University Oligomères ioniques de type imidazolium

Also Published As

Publication number Publication date
DK593489A (da) 1990-06-02
AU4553889A (en) 1990-06-07
EP0371730A1 (fr) 1990-06-06
DK593489D0 (da) 1989-11-24
JPH02193978A (ja) 1990-07-31
PT92473A (pt) 1990-06-29

Similar Documents

Publication Publication Date Title
US4798843A (en) 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
US4835154A (en) 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
EP0219961B1 (fr) Inhibiteurs irréversibles pour la dopamine-B-hydroxylase
US4719223A (en) Imidazolethiol dopamine-beta-hydroxylase inhibitors
EP0250264A1 (fr) Inhibiteurs de dopamine-bêta-hydroxylase à effet irréversible
CA2002247A1 (fr) Inhibiteurs de la dopamine-.beta.-hydroxylase
US4882348A (en) 2-(aminoalkylthio)imidazoles as dopamine-β-hydroxylase inhibitors
US4935438A (en) Dopamine-β-hydroxylase inhibitors
US4749717A (en) Dopamine-beta-hydroxylase inhibitors
US4762850A (en) Dopamine-beta-hydroxylase inhibitors
EP0244956A1 (fr) Précurseurs du type ester d'inhibiteurs de dopamine-bêta-hydroxylase
EP0246888A2 (fr) Inhibiteurs de dopamine-bêta-hydroxylase
CA2002246A1 (fr) Inhibiteurs de la dopamine-.beta.-hydroxylase
US4628059A (en) Dopamine-β-hydroxylase inhibitors
EP0371733A2 (fr) Inhibiteurs de dopamine-bêta-hydroxylase
US4859779A (en) Dopamine-β-hydroxylase inhibitors
CA1271767A (fr) INHIBITEURS DE LA DOPAMINE-.beta.-HYDROXYLASE
US4837353A (en) Dopamine-β-hydroxylase inhibitors
WO1989006126A1 (fr) 1-ARALKYL-2-MERCAPTOIMIDAZOLINES A USAGE D'INHIBITEURS DE LA DOPAMINE-beta-HYDROXYLASE
US4912226A (en) Intermediate to dopamine-β-hydroxylase inhibitors
US4873357A (en) Trifluoro acetyl-cyano-aniline intermediates for dopamine-βhydroxylase inhibitors
US4810811A (en) Dopamine-beta-hydroxylase inhibitors
EP0285356A2 (fr) Inhibiteurs de dopamine-bèta-hydroxylase

Legal Events

Date Code Title Description
FZDE Dead